NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis $0.14 0.00 (-2.71%) As of 12:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About Hepion Pharmaceuticals Stock (NASDAQ:HEPA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hepion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.14▼$0.1450-Day Range$0.05▼$0.1852-Week Range$0.03▼$0.22Volume20,060 shsAverage Volume26,532 shsMarket Capitalization$1.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. The company’s research has centered on conditions including metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), chronic hepatitis B, and other diseases involving liver fibrosis and inflammation. Hepion’s lead investigational product, rencofilstat (formerly known as CRV431), is an oral cyclophilin inhibitor designed to address biological pathways associated with liver disease progression. The compound has been evaluated for potential applications in MASH and chronic hepatitis B, although it remains an investigational therapy and is not approved for commercial use. The company was formerly known as ContraVir Pharmaceuticals and adopted the Hepion Pharmaceuticals name in 2019. Its operations have primarily focused on research and clinical development rather than the sale of marketed products, with development activities conducted through clinical and research programs intended to support future regulatory approval.AI Generated. May Contain Errors. Read More Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEPA Stock News HeadlinesHepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac ArrestOctober 26, 2026 | usatoday.comHepion Pharmaceuticals Expands Authorized Share Capital for GrowthOctober 2, 2026 | tipranks.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.November 4 at 1:00 AM | Profits Run (Ad)Hepion Pharmaceuticals Announces New Private Placement FinancingAugust 4, 2026 | tipranks.comHepion Shareholders Expand Equity Plan at 2026 MeetingJune 17, 2026 | tipranks.comHepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comHepion Finalizes CEO Separation Agreement Amid Leadership TransitionApril 14, 2026 | tipranks.comHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaMarch 3, 2026 | globenewswire.comSee More Headlines HEPA Stock Analysis - Frequently Asked Questions How have HEPA shares performed this year? Hepion Pharmaceuticals' stock was trading at $0.06 at the beginning of 2026. Since then, HEPA stock has increased by 141.7% and is now trading at $0.1450. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) released its earnings results on Thursday, August, 13th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($200.00) by $199.92. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals's stock reverse split on Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include 9 Meters Biopharma (NMTR), Sorrento Therapeutics (SRNE), SNDL (SNDL), Atossa Genetics (ATOS), Ideanomics (IDEX), iBio (IBIO) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings8/13/2026Today11/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HEPA CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees20Year Founded2013Profitability EPS (Trailing Twelve Months)($72.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-812.56% Return on Assets-207.31% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.11Miscellaneous Outstanding Shares11,435,000Free Float6,631,000Market Cap$1.60 million OptionableNo Data Beta1.52 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:HEPA) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc (OTCQB: VDTA) is building the layers beneath the AI boom - GPU hardware and financing, manag...Trading Wire | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
